Literature DB >> 26962268

Drug Design Strategies for GPCR Allosteric Modulators.

P Jeffrey Conn1, Scott D Kuduk2, Darío Doller3.   

Abstract

Entities:  

Year:  2012        PMID： 26962268      PMCID： PMC4780677          DOI： 10.1016/B978-0-12-396492-2.00028-X

Source DB:  PubMed          Journal:  Annu Rep Med Chem        ISSN： 0065-7743            Impact factor:   1.059


× No keyword cloud information.
  39 in total

1.  Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival.

Authors:  Paul Morgan; Piet H Van Der Graaf; John Arrowsmith; Doug E Feltner; Kira S Drummond; Craig D Wegner; Steve D A Street
Journal:  Drug Discov Today       Date:  2011-12-29       Impact factor: 7.851

2.  Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades.

Authors:  Hannah K Delille; Judith M Becker; Sabrina Burkhardt; Barbara Bleher; Georg C Terstappen; Martin Schmidt; Axel H Meyer; Liliane Unger; Gerard J Marek; Mario Mezler
Journal:  Neuropharmacology       Date:  2012-01-25       Impact factor: 5.250

3.  Identification and characterization of mGlu3 ligands using a high throughput FLIPR assay for detection of agonists, antagonists, and allosteric modulators.

Authors:  Steven D Pratt; Mario Mezler; Hervé Geneste; Margot H M Bakker; Philip J Hajduk; Sujatha M Gopalakrishnan
Journal:  Comb Chem High Throughput Screen       Date:  2011-08       Impact factor: 1.339

Review 4.  The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors.

Authors:  Celine Valant; J Robert Lane; Patrick M Sexton; Arthur Christopoulos
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011-09-09       Impact factor: 13.820

5.  A simple method for quantifying functional selectivity and agonist bias.

Authors:  Terry Kenakin; Christian Watson; Vanessa Muniz-Medina; Arthur Christopoulos; Steven Novick
Journal:  ACS Chem Neurosci       Date:  2011-12-20       Impact factor: 4.418

6.  Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects.

Authors:  Celine Valant; Christian C Felder; Patrick M Sexton; Arthur Christopoulos
Journal:  Mol Pharmacol       Date:  2011-10-11       Impact factor: 4.436

7.  Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening.

Authors:  Cassandra Koole; Denise Wootten; John Simms; Celine Valant; Rohan Sridhar; Owen L Woodman; Laurence J Miller; Roger J Summers; Arthur Christopoulos; Patrick M Sexton
Journal:  Mol Pharmacol       Date:  2010-06-14       Impact factor: 4.436

Review 8.  The 7 TM G-protein-coupled receptor target family.

Authors:  Edgar Jacoby; Rochdi Bouhelal; Marc Gerspacher; Klaus Seuwen
Journal:  ChemMedChem       Date:  2006-08       Impact factor: 3.466

9.  Transformation of Pro-Leu-Gly-NH2 peptidomimetic positive allosteric modulators of the dopamine D2 receptor into negative modulators.

Authors:  Swapna Bhagwanth; Satyendra Mishra; Ritesh Daya; Jordan Mah; Ram K Mishra; Rodney L Johnson
Journal:  ACS Chem Neurosci       Date:  2012-01-13       Impact factor: 4.418

Review 10.  Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors.

Authors:  Eric Reiter; Seungkirl Ahn; Arun K Shukla; Robert J Lefkowitz
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011-09-19       Impact factor: 13.820
View more
  5 in total

Review 1.  Ligand binding at the protein-lipid interface: strategic considerations for drug design.

Authors:  Jian Payandeh; Matthew Volgraf
Journal:  Nat Rev Drug Discov       Date:  2021-07-13       Impact factor: 84.694

Review 2.  Development of allosteric modulators of GPCRs for treatment of CNS disorders.

Authors:  Hilary Highfield Nickols; P Jeffrey Conn
Journal:  Neurobiol Dis       Date:  2013-09-27       Impact factor: 5.996

3.  Screening for positive allosteric modulators of cholecystokinin type 1 receptor potentially useful for management of obesity.

Authors:  Daniela G Dengler; Qing Sun; Kaleeckal G Harikumar; Laurence J Miller; Eduard A Sergienko
Journal:  SLAS Discov       Date:  2022-07-16       Impact factor: 3.341

Review 4.  Shared Behavioral and Neurocircuitry Disruptions in Drug Addiction, Obesity, and Binge Eating Disorder: Focus on Group I mGluRs in the Mesolimbic Dopamine Pathway.

Authors:  Samantha E Yohn; Jordan Galbraith; Erin S Calipari; P Jeffrey Conn
Journal:  ACS Chem Neurosci       Date:  2019-04-15       Impact factor: 4.418

5.  Analysis of tractable allosteric sites in G protein-coupled receptors.

Authors:  Amanda E Wakefield; Jonathan S Mason; Sandor Vajda; György M Keserű
Journal:  Sci Rep       Date:  2019-04-16       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.